600521 华海药业
2025/03 - 三个月
人民幣(K¥)
与去年同期
比较
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
营业总收入2,368,564-5.21%9,547,4258,308,7208,265,7456,643,573
减:营业总成本2,002,447-4.60%7,978,7397,096,9006,635,6946,300,680
    其中:营业成本834,236-17.08%3,636,6043,288,3383,110,9362,657,134
               财务费用47,47313.81%95,480137,247(10,833)188,184
               资产减值损失(19,484)-844.03%(122,874)(117,176)(70,604)(13,928)
公允价值变动收益13,254-122.54%(69,493)(100,248)5,201299,808
投资收益(8,002)11.56%(28,720)(62,652)(75,205)147,151
    其中:对联营企业和合营企业的投资收益(8,036)6.41%(28,660)(27,700)(42,191)(41,774)
营业利润376,7690.57%1,470,7891,124,5401,547,171868,399
利润总额375,0120.85%1,463,6081,100,3211,508,900786,928
减:所得税费用78,973-19.33%356,145283,072332,890306,284
净利润296,0408.07%1,107,463817,2491,176,009480,644
减:非控股权益(1,364)-143.99%(11,518)(13,217)8,251(6,891)
股东净利润297,4049.81%1,118,981830,4661,167,759487,535

市场价值指针
每股收益 (元) *0.21010.53%0.7700.5700.8100.340
每股派息 (元) *----0.2500.2000.2400.100
每股净资产 (元) *6.32616.08%5.9035.2864.925--
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容